BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...concentration of target T cells needed to trigger the therapeutic effects in EAE. GlaxoSmithKline plc's AnergiX...
BioCentury | Jan 22, 2002
Company News

Corixa, Beaufour Ipsen Group deal

...CRXA granted Beaufour exclusive worldwide rights to its AnergiX.MG T cell inactivation technology to treat myasthenia...
BioCentury | Jan 15, 2002
Company News

Corixa licenses AnergiX.MG to Beaufour

...CRXA granted Beaufour Ipsen (Paris, France) exclusive worldwide development and marketing rights to its AnergiX.MG T...
BioCentury | Jan 8, 2001
Company News

Corixa, N.V. Organon deal

...which CRXA acquired in 1999, to include the development of a recombinant form of Anergen's AnergiX.RA...
...the natural form of the compound. Under the amended agreement, Organon and CRXA will share AnergiX.RA...
...an option to co-promote AnergiX.RA in the U.S. Results of a Phase I/II trial of AnergiX.RA...
BioCentury | Jan 3, 2001
Company News

Corixa amends agreement with Organon

...CRXA acquired in 1999, to include the continued development of a recombinant form of Anergen's AnergiX.RA...
...complex to treat rheumatoid arthritis (RA). Under the amended agreement, Organon and CRXA will share AnergiX.RA...
...an option to co-promote AnergiX.RA in the U.S. Results of a Phase I/II trial of AnergiX.RA...
BioCentury | Nov 6, 2000
Clinical News

AnergiX: Phase I/II

...Final results from CRXA's 31-patient Phase I/II trial showed that AnergiX.RA was safe and well tolerated...
...product is partnered with N.V. Organon (Oss, the Netherlands). Corixa Corp. (CRXA), Seattle, Wash. Product: AnergiX.RA...
BioCentury | Oct 23, 2000
Strategy

Growing a pipeline

...Phase II Psoriasis AnervaX.RA vaccine Phase II Rheumatoid arthritis AnergiX.RA vaccine Phase II Rheumatoid arthritis AnergiX.MS...
BioCentury | Apr 24, 2000
Company News

Corixa, N.V. Organon deal

...in 1999. The milestone was triggered by completion of a Phase I/II trial of CRXA's AnergiX.RA...
BioCentury | Nov 22, 1999
Clinical News

AnergiX: Phase I

...Data from 31 patients showed that AnergiX.RA was safe and well tolerated at doses ranging from...
...in Boston. The product is partnered with N.V. Organon. Corixa Corp. (CRXA), Seattle, Wash. Product: AnergiX.RA...
BioCentury | Oct 26, 1998
Clinical News

AnergiX AG284 myelin basic protein complexed to HLA-DR2 major histocompatibility complex molecule: Phase I

...and Research in Multiple Sclerosis meeting in Montreal. Anergen Inc. (ANRG), Redwood City, Calif. Product: AnergiX...
Items per page:
1 - 10 of 33
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...concentration of target T cells needed to trigger the therapeutic effects in EAE. GlaxoSmithKline plc's AnergiX...
BioCentury | Jan 22, 2002
Company News

Corixa, Beaufour Ipsen Group deal

...CRXA granted Beaufour exclusive worldwide rights to its AnergiX.MG T cell inactivation technology to treat myasthenia...
BioCentury | Jan 15, 2002
Company News

Corixa licenses AnergiX.MG to Beaufour

...CRXA granted Beaufour Ipsen (Paris, France) exclusive worldwide development and marketing rights to its AnergiX.MG T...
BioCentury | Jan 8, 2001
Company News

Corixa, N.V. Organon deal

...which CRXA acquired in 1999, to include the development of a recombinant form of Anergen's AnergiX.RA...
...the natural form of the compound. Under the amended agreement, Organon and CRXA will share AnergiX.RA...
...an option to co-promote AnergiX.RA in the U.S. Results of a Phase I/II trial of AnergiX.RA...
BioCentury | Jan 3, 2001
Company News

Corixa amends agreement with Organon

...CRXA acquired in 1999, to include the continued development of a recombinant form of Anergen's AnergiX.RA...
...complex to treat rheumatoid arthritis (RA). Under the amended agreement, Organon and CRXA will share AnergiX.RA...
...an option to co-promote AnergiX.RA in the U.S. Results of a Phase I/II trial of AnergiX.RA...
BioCentury | Nov 6, 2000
Clinical News

AnergiX: Phase I/II

...Final results from CRXA's 31-patient Phase I/II trial showed that AnergiX.RA was safe and well tolerated...
...product is partnered with N.V. Organon (Oss, the Netherlands). Corixa Corp. (CRXA), Seattle, Wash. Product: AnergiX.RA...
BioCentury | Oct 23, 2000
Strategy

Growing a pipeline

...Phase II Psoriasis AnervaX.RA vaccine Phase II Rheumatoid arthritis AnergiX.RA vaccine Phase II Rheumatoid arthritis AnergiX.MS...
BioCentury | Apr 24, 2000
Company News

Corixa, N.V. Organon deal

...in 1999. The milestone was triggered by completion of a Phase I/II trial of CRXA's AnergiX.RA...
BioCentury | Nov 22, 1999
Clinical News

AnergiX: Phase I

...Data from 31 patients showed that AnergiX.RA was safe and well tolerated at doses ranging from...
...in Boston. The product is partnered with N.V. Organon. Corixa Corp. (CRXA), Seattle, Wash. Product: AnergiX.RA...
BioCentury | Oct 26, 1998
Clinical News

AnergiX AG284 myelin basic protein complexed to HLA-DR2 major histocompatibility complex molecule: Phase I

...and Research in Multiple Sclerosis meeting in Montreal. Anergen Inc. (ANRG), Redwood City, Calif. Product: AnergiX...
Items per page:
1 - 10 of 33